J. Durkee-Shock

Transcriptomic analysis reveals optimal cytokine combinations for SARS-CoV-2-specific T cell therapy products

Christopher A. Lazarski, P. Hanley, C. Bollard, 2022, Molecular Therapy - Methods & Clinical Development.

Immunizing the imperfect immune system

M. Keller, J. Durkee-Shock, 2022, Annals of Allergy, Asthma & Immunology.

Robust Antibody and T Cell Responses to SARS-CoV-2 in Patients with Antibody Deficiency

Christopher A. Lazarski, L. Notarangelo, C. Bollard, 2021, Journal of Clinical Immunology.

SARS-CoV-2–specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein

Christopher A. Lazarski, N. Zhang, P. Hanley, 2020, Blood.

SARS-CoV-2-Specific T Cell Responses Are Stronger in Children With Multisystem Inflammatory Syndrome Compared to Children With Uncomplicated SARS-CoV-2 Infection

Christopher A. Lazarski, R. DeBiasi, C. Bollard, 2022, Frontiers in Immunology.

Antibody responses to the SARS-CoV-2 vaccine in individuals with various inborn errors of immunity

L. Notarangelo, S. Holland, K. Dobbs, 2021, Journal of Allergy and Clinical Immunology.

SARS-CoV-2–specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein

Christopher A. Lazarski, P. Hanley, C. Bollard, 2020, Blood.

Recurrent lymphadenitis in a female XIAP/BIRC4 mutation carrier with normal lyonization.

S. Rosenzweig, J. Milner, H. Kuehn, 2020, The journal of allergy and clinical immunology. In practice.